Signs and symptoms of congestion are the most common cause for hospitalization for heart failure (HHF). The clinical course and prognostic value of congestion during HHF has not been systemically characterized.
Introduction
Hospitalization for heart failure (HHF) account for over 1.1 million admissions and greater than $20 billion in healthcare expenditures each year in the USA. 1, 2 Signs and symptoms of congestion are the most common cause for HHF and readmission. 3 As a result, alleviating clinical congestion has traditionally been one of the primary goals of management during hospitalization. 4, 5 Registry data reveal that 40% of patients are discharged despite persistent signs and symptoms of HF with minimal decrease or even an increase in body weight, suggesting failure to relieve clinical congestion during index hospitalization may potentially contribute to the high post-discharge readmission rate. 6 -8 However, the prevalence and severity of residual congestive signs and symptoms at discharge is likely inversely related to the length of stay, which exhibits considerable geographic variation and is known to be shorter in the USA compared with Europe. 9 The Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial provides a unique opportunity to systemically and longitudinally study the natural history of congestive signs and symptoms in response to standard therapy in a large contemporary cohort of patients hospitalized for worsening HF with reduced ejection fraction (EF). Specifically, the objectives of this analysis were: (i) to describe the clinical course of signs and symptoms of congestion and (ii) to evaluate the association between clinical congestion at discharge and post-discharge morbidity and mortality.
Methods

Study overview
The study design 10 and primary results 11, 12 of the EVEREST trial have been previously reported. Briefly, EVEREST was a global, prospective, randomized, double-blind, placebo-controlled trial designed to examine the short-and long-term efficacy and safety of tolvaptan, a vasopressin-2 receptor antagonist. Patients ≥18 years of age, hospitalized for worsening HF, with a left ventricular ejection fraction (LVEF) ≤40%, symptoms classified as New York Heart Association (NYHA) III or IV, and two or more signs or symptoms of volume overload [dyspnoea, pitting oedema, and jugular venous distension (JVD)] at presentation were enrolled within 48 h (median 24 h). Relevant exclusion criteria included systolic blood pressure (SBP) ,90 mmHg, haemodynamically significant uncorrected primary cardiac valvular disease, serum creatinine (sCr) .3.5 mg/dL or 309.4 mmol/L, subjects currently treated with haemofiltration or dialysis, or a life expectancy of ,6 months as determined by the enrolling clinician-investigator.
Background HF therapy was left to the discretion of the treating physician, but guideline-based recommendations for optimal medical management were included in the study protocol. EVEREST was conducted in accordance with the Declaration of Helsinki, the protocol was independently approved by the Institutional Review Board or ethics committee at each participating centre, and written informed consent was obtained from all participants. The present analysis includes only patients randomized to the placebo group (n ¼ 2061), since tolvaptan has previously been reported to improve dyspnoea and decrease body weight. 11 
Investigator-assessed signs and symptoms of congestion
Patients were examined daily during hospitalization by physician-investigators for signs and symptoms of congestion from the time of enrolment until discharge or hospital day 7, whichever occurred first. Dyspnoea, fatigue, orthopnoea, JVD, rales, and pedal oedema were assessed on a standardized 4-point scale ranging from 0 to 3 ( Table 1) . A composite congestion score (CCS) was calculated by summing the individual scores for orthopnoea, JVD, and pedal oedema based on a precedent set by a prior study which assessed signs and symptoms of congestion at an initial follow-up visit scheduled between 4 and 6 weeks post-discharge. 13 In addition, orthopnoea, JVD, and pedal oedema were selected a priori in order to (i) avoid redundancy regarding the severity of congestion and (ii) include a diverse set of signs and symptoms known to have high specificity for congestion. 14 -16 
EVEREST endpoints
An independent and blinded adjudication committee determined the cause of all hospitalizations and deaths reported during follow-up. The outcomes of interest for the present analysis were HHF, all-cause mortality (ACM), and the composite of ACM + HHF. Hospitalization for heart failure was defined as admission that extended over a change in calendar day and included worsening signs or symptoms of HF resulting in the augmentation of oral medications or new administration of intravenous HF therapies or ultrafiltration.
Statistical analysis
Patients were divided into four groups based on CCS at discharge (0, 1, 2, and 3 -9). Baseline demographic, medical history, physical exam, and laboratory findings were compared using Kendall's rank correlation test for continuous and ordered categorical variables and Pearson's x 2 test for unordered categorical variables. The associations between discharge CCS and HHF, ACM, and ACM + HHF were assessed using univariate and multivariate Cox proportional-hazard models adjusted for age, LVEF, previous HHF, SBP at enrolment, b-type natriuretic peptide (BNP)/amino terminal-proBNP (NT-proBNP), blood urea nitrogen (BUN), serum sodium, baseline diuretic usage, and discharge medications (i.e. b-blockers, lipid-lowering agents, and amiodarone). The model for adjustment was determined through a process of backward selection with ACM as the endpoint. The least significant candidate variables were removed until all remaining variables were significant. Hazard ratios are presented with 95% confidence intervals.
Funding and manuscript preparation
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Results
Study population
Between October 2003 and February 2006, 2061 patients were assigned to the placebo arm of the EVEREST trial. Study participants had a mean age of 65.6 + 12.0 years, approximately threequarters were male, and the vast majority self-identified their race as white. Patients had a mean EF of 27.5 + 8.2% and most had an ischaemic aetiology of HF. Nearly 80% of participants reported a prior history of HHF and presented with New York Heart Association (NYHA) class III or IV symptoms. The prevalence of medical comorbidities was high. Patients were well-treated with evidence-based therapies including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, b-blockers, and mineralocorticoid receptor antagonists.
Baseline characteristics by discharge congestion
Patients with higher CCS at discharge/day 7 were more likely to report a prior history of HHF, a higher prevalence of medical comorbidities (e.g. diabetes mellitus, severe chronic obstructive pulmonary disease, and chronic kidney disease), and prior revascularization (i.e. percutaneous coronary intervention or coronary artery bypass graft) or medical device therapy (i.e. automated implantable cardioverter-defibrillator or pacemaker) ( Table 2) . They were also more likely to be classified as NYHA IV. Notably, pulmonary rales were found to be the least prevalent in patients with a discharge CCS of 3-9. Finally, patients with more signs and symptoms of congestion at discharge were found to have a lower EF and were more likely to have a prolonged QRS duration and abnormal basic laboratory (i.e. BUN and sCr) and neurohormonal profile [i.e. BNP/NT-proBNP and arginine vasopressin (AVP)].
Clinical course of congestion during hospitalization
There was significant improvement in the distribution of CCS from baseline to discharge/Day 7 ( Figure 1) . The CCS decreased from a mean + SD of 4.07 + 1.84 and median (25th, 75th) of 4 (3, 5) at baseline to 1.11 + 1.42 and 1 (0, 2) at discharge. Among patients with a baseline CCS of 2 and 3-9, respectively, 62.5 and 88.8% experienced a decrease in CCS of 2 or greater (Supplementary material online, Table S1 ). By discharge, nearly three-quarters of study participants had a CCS of 0 or 1 and fewer than 10% of patients had a CCS score . 3 . The decrease in CCS occurred concurrently with a sustained body weight reduction of 22.1 (24.1, 20.8) kg. B-type natriuretic peptide and NT-proBNP, respectively, decreased from 734 (313, 1523) pg/mL and 4857 (2251, 9642) pg/ mL at baseline to 477 (199, 1079) pg/mL and 2834 (1218, 6075) pg/mL at discharge/Day 7.
Patients with a CCS at discharge of 0 -2 and 3-9, respectively, had the CCS of 3.81 + 1.76; 4 (2, 5) and 5.47 + 1.58; 0 (0, 1) at baseline and 0.61 + 0.73; 6 (4, 7) and 3.86 + 1.12; 3 (3, 4) at discharge/Day 7 ( Table 3) . Although both groups experienced comparable body weight reductions, patients with a discharge CCS of 3-9 reported more signs and symptoms of HF and a substantially higher concentration of BNP and NT-proBNP at discharge/Day 7. Finally, patients with a discharge CCS of 3-9 had worse renal function (i.e. estimated glomerular filtration rate) both at baseline and discharge/Day 7.
Discharge congestion score and long-term outcomes
During a median follow-up of 9.9 months, patients with a CCS at discharge of 0 and 3-9, respectively, experienced HHF of 26.2% (n ¼ 233) and 34.7% (n ¼ 103) and ACM of 19.1% (n ¼ 170) and 42.8% (n ¼ 127) ( Table 4) . After adjusting for potential confounders (Supplementary material online, Table S2 ), discharge CCS was associated with an increased risk of ACM, and ACM + HHF both at 30 days and for the overall study period ( Figure 2 and Table 5 ). Discharge CCS was associated with HHF over the duration of the study but not at 30 days.
Discussion
To the best of our knowledge, this is the first global study to describe the clinical course and predictive value of congestive signs and symptoms in patients hospitalized for worsening HF with reduced EF in the context of a clinical trial with daily monitoring. Clinical congestion improved rapidly and dramatically in response to standard therapy with minimal or absent signs and symptoms at discharge. Although improvements in signs and symptoms of congestion occurred concurrently with body weight decreases, BNP/NT-proBNP remained markedly elevated at discharge. Clinical congestion at discharge was associated with an increased risk of 30-day and overall ACM and ACM + HHF as well as overall HHF. However, patients with absent or minimal signs and symptoms of congestion at discharge still experienced a high mortality and readmission rate. 
. 
Clinical course of congestive signs and symptoms
It is notable that moderate-to-severe signs and symptoms of congestion were present at baseline assessment, which occurred up to 48 h after admission, well after the timeframe traditionally ascribed to the very acute phase. Previous research has demonstrated that with early initiation of standard therapy dyspnoea measured in a seated and upright position improved substantially within 6 h of initial presentation. 17 This finding suggests that initial therapy may have been delayed in the EVEREST trial due to diagnostic uncertainty, or, alternatively, dyspnoea may resolve more rapidly and improvement in other congestive signs (e.g. JVP and pedal oedema) and symptoms (e.g. orthopnoea) may lag behind temporally. In contrast, by discharge close to 85% of patients enrolled in the EVEREST trial were found to have minimal or no signs or symptoms of congestion. Traditionally, relieving dyspnoea has been the primary endpoint for short-term efficacy in pivotal clinical trials in HF. 18 The observation that standard therapy rapidly and dramatically improved clinical congestion suggests that it may be difficult for novel therapies to 'beat' placebo.
A more unexpected outcome is the finding that pulmonary rales were the least prevalent among patients with the highest CCS. This seemingly paradoxical finding may be at least partially explained by a bias towards right-sided HF signs (i.e. JVD and pedal oedema) in defining CCS and the fact that the prevalence of pulmonary rales may not accurately reflect the severity.
Dissociation between clinical and haemodynamic congestion
It should be emphasized that although patients experienced improvements in congestive signs and symptoms concomitantly with a sustained reduction in body weight, BNP/NT-proBNP decreased but remained markedly elevated at discharge. Conceptually, volume overload has been subdivided into 'clinical' and 'haemodynamic' congestion. 3, 9, 19 Clinical congestion manifests as signs and symptoms of volume overload (e.g. dyspnoea, orthopnoea, JVD, etc.), while haemodynamic congestion has been defined as elevated cardiac filling pressures with or without clinical congestion. Haemodynamic congestion may be present days or weeks prior to admission for AHFS and resolution during hospitalization may be delayed or incomplete despite aggressive diuresis. The finding that BNP/NT-proBNP remained significantly elevated despite improvements in signs and symptoms of congestion highlights the disassociation between clinical and haemodynamic congestion. Persistent haemodynamic congestion is thought to contribute to the pathophysiological progression of HF, suggesting that alleviating signs and symptoms without correcting underlying subclinical haemodynamic abnormalities may be insufficient. This hypothesis is further supported by the fact that higher natriuretic peptide concentration has been shown to be one of the strongest predictors of morbidity and mortality both at discharge 20 and at 1-week post-discharge. 21 
Distinguishing between responders and non-responders
A number of clinically interesting findings emerged when patients were subdivided into 'responders' (i.e. CCS 0-2) and 'nonresponders', or perhaps more accurately 'partial responders' (i.e. CCS 3-9), at discharge. First, in interpreting these data it should be reiterated that the majority of patients enrolled in the EVEREST trial responded rapidly and dramatically in response to standard therapy alone and only 15% of patients were discharged with a CCS ≥3. However, it is notable that although responders and non-responders had clinically, although not numerically, comparable signs and symptoms of congestion at baseline (e.g. dyspnoea) there were substantial between-group differences in neurohormonal markers of haemodynamic congestion (i.e. BNP/NT-proBNP and AVP) and more subtle discrepancies in renal function parameters (i.e. sCr and BUN).
In contrast, at discharge, by definition, responders exhibited minimal or no signs and symptoms of HF while non-responders manifested signs and symptoms similar in severity to responders at baseline. Baseline renal impairment and worsening renal function during hospitalization are markers of more severe HF requiring high-dose diuretic therapy to maintain fluid homoeostasis, perhaps at least partially explaining the disparity in congestion relief observed in the present analysis. 22, 23 However, it is difficult to hypothesize whether diuresis was impeded or intentionally limited in non-responders by renal dysfunction.
Treating beyond resting signs and symptoms of congestion
It has been previously established the congestive signs and symptoms are associated with increased morbidity and mortality at initial presentation, 24 following index hospitalization, 13 and in the ambulatory setting. 25 The present analysis found clinical congestion at discharge to be predictive of post-discharge mortality and rehospitalization for HF. This finding is clinically relevant since signs and symptoms of congestion are the most common cause for HHF and readmission, an important therapeutic target of inpatient Clinical course and predictive value of congestion management, and a major determinant of discharge decisionmaking. 4, 5 However, despite the clinical importance of targeting signs and symptoms during hospitalization, patients with absent or minimal signs and symptoms of congestion experienced a postdischarge event rate comparable in magnitude to the overall cohort. This finding raises the hypothesis that treating beyond resolution of resting signs and symptoms of congestion may mediate improvements in post-discharge outcomes. 26, 27 Further research is necessary to prospectively validate the clinical utility of targeting provocative manoeuvres including an assessment of orthopnoea and completion of a 6-minute walk test and circulating biomarkers such as BNP/NT-proBNP in patients hospitalized for heart failure.
Limitations
There are several limitations of the data. First, this study was performed post hoc and is subject to the potential biases inherent to exploratory analyses of observational data. Nonetheless, signs and symptoms were assessed daily by clinician-investigators using a standardized scoring scale and events were adjudicated by a blinded, independent events committee. Secondly, the study protocol required two or more signs or symptoms of volume overload (dyspnoea, pitting oedema, or JVD) at presentation, which have may have selected for patients with a higher prevalence and greater severity of congestive signs and symptoms. However, enrolment was permitted up to 48 h (median 24 h) after admission and patients likely had already received diuretic therapy. 
. it is conceivable that baseline signs and symptoms of congestion may have been even more severe had patients been enrolled closer to the time of presentation or alternatively patients may have been more refractory to diuretic therapy. In addition, patients with a baseline SBP ,90 mmHg, haemodynamically significant uncorrected primary cardiac valvular disease, and a sCr concentration . 3 .5 mg/dL (or currently receiving haemofiltration, or dialysis) were excluded, greatly limiting the applicability of this study's major findings to low output states and patients with primary valvular pathology or severe renal impairment. Finally, these data were collected in the context of a clinical trial with specific inclusion and exclusion criteria and patients were well-treated with background evidenced-based therapies and had pre-specified post-discharge follow-up, potentially restricting the generalizability of this analysis.
Conclusion
In a trial, congestive signs and symptoms improved rapidly and substantially in response to standard therapy alone, suggesting it may be difficult for investigational treatments to alleviate clinical congestion beyond that seen with standard therapy alone (i.e. placebo). Notably, there is a disassociation between relief of signs and symptoms of volume overload and subclinical haemodynamic congestion (i.e. elevated natriuretic peptide).
Although clinical congestion at discharge was directly associated with subsequent mortality and readmission, absent or minimal signs and symptoms of congestion did not portend a good post-discharge prognosis, raising the hypothesis that clinical 'decongestion' may be insufficient. Accordingly, assessing and grading congestion during hospitalization and pre-discharge should move beyond a basic bedside determination of resting signs and symptoms in favor of a more comprehensive evaluation, incorporating dynamic maneuvers (i.e. orthopnea, 6-minute walk test, etc.) and hemodynamic biomarkers (i.e. BNP/NT-proBNP), in order to guide therapy and discharge decision making. 9 
